LOW CD34 CELL DOSE IS ASSOCIATED WITH HIGHER NON-RELAPSE AND OVERALL MORTALITY AFTER REDUCED INTENSITY CONDITIONING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME

¹Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital,²Division of Therapeutic Immunology, Karolinska Institutet, Stockholm, Sweden,³Center for International Blood & Marrow Transplantation Research, Medical College of Wisconsin, Milwaukee, WI,⁴Heart, Lung, and Blood Institute, Hematology Branch, National Institutes of Health, Bethesda, MD,⁵Center for International Blood & Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI,⁶Dana-Farber Cancer Institute, Boston, MA,⁷Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX,⁸Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI,⁹University of Virginia Medical Center, Charlottesville, VA,¹⁰Seidman Cancer Center, University Hospitals Case Medical Center,¹¹Cleveland Cord Blood Center, Cleveland, OH,¹²Cedars-Sinai Medical Center, Los Angeles, CA, United States,¹³Centre for Children's Cancer & Blood Disorders, Sydney Children's Hospital, Sydney, Australia,¹⁴Memorial Sloan-Kettering Cancer Center, New York, NY, United States,¹⁵Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom,¹⁶Vanderbilt University Medical Center, Nashville, TN, United States,¹⁷CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada,¹⁸Hospital Infantil Vall d'Hebron, Barcelona, Spain